Clinical Trial Update: Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of rhPTH(1-84) in hypoparathyroidism was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• rhPTH(1-84) (recombinant human parathyroid hormone 1-84)

Snippet

Sponsor: Shire | Conditions: Hypoparathyroidism | Phase 3 | Status: TERMINATED | Results posted: 2021-06-16